


MaaT Pharma

Boosting Survival Through Innovative Immune Modulation





Disclaimer

This document has been prepared by MaaT Pharma (the "Company") and is for information and background purposes only.

While the information contained herein has been prepared in good faith, neither the Company, nor its shareholders, directors, officers, agents, employees, or advisors give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the fairness, accuracy, reliability or completeness of the information in this document, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers, including financial information (all such information being referred to as "Information"), and liability therefor is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees, affiliates, representatives or advisers take any responsibility for, or will accept any liability whether direct or indirect express or implied, contractual, tortuous, statutory or otherwise, in respect of the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising from this document.

The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised, verified or amended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the information or opinions contained herein which are subject to change without prior notice. The information contained in this document has not been subject to independent verification and are qualified in their entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on the regulated market of Euronext in Paris, including in particular the risk factors and other information in the Company's Document d'enregistrement (Registration Document) registered by the French Autorité des marches financiers (Financial Markets Authority) (the "AMF") on October 1st, 2021 under no. I.21-0057 and its supplement on October 14, 2021 under no. I.21-0061 and in any other periodic report, which are available free of charge on the websites of the Company (https://www.maatpharma.com/) and the AMF (www.amf-france.org).

No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.

This document contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates which may not be accurate and thus no reliance should be placed on such information. Any prospective investors must make their own investigation and assessments and consult with their own advisers concerning any evaluation of the Company and its prospects, and this document, or any part of it, may not form the basis of or be relied on in connection with any investment decision. This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable.


Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forwardlooking statements cannot, under any circumstance, be construed as a guarantee of the Company's future performance and the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Even if the Company's financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this document.

All persons accessing this document are deemed to agree to all the limitations and restrictions set out above.

З

Management Team





Company Overview

MaaT013 in aGvHD: Primary Endpoint of Phase 3 Study Achieved Registration in Europe Spearheading Microbiome Therapies in Oncology



<u>Now available:</u> Phase 3 Data in aGvHD from the ARES study

\diamond	Primary endpoint: unprecedented,
	GI-ORR [*] of 62% in patients having
	previously received steroids and
	ruxolitinib

> High response rate leading to prolonged		
survival, highlighting MaaT013's potential		
to overcome the short-term mortality of		
third-line GI-aGvHD		

 Company anticipates MAA submission in Europe, in mid-2025, earlier than initially planned



Multi-assets platform focused on oncology

- Full ecosystem donor-derived and co-culture platforms driving candidate development with 2 clinical and 1 preclinical assets
- gutPrint® AI, linked to co-culture platform, poised to deliver, potentially, clinically-ready candidates by 2026
- ▶ Largest European cGMP production facilities for Microbiome Ecosystem Therapies[™]

Funding opportunities

- Cash position of 27m€ as of September 30, 2024. Cash runway extends into Q2/2025
- Potential 750m€ yearly peak sales
 Hemato-Onco franchise for partnering:
 250m€ for MaaT013 in GvHD and 500m€
 for MaaT033 in allo-HSCT.
- Exploring several options to strengthen financing for future developments, including non-dilutive and dilutive sources

LISTED


Correcting Dysbiosis: a New Pillar in Oncology

Dysbiosis and disease

- Loss of microbial diversity
- Increase in pathogens
- Reduction of **microbial metabolites**
- Associated with multiple conditions


Microbiome alterations in Oncology

- **Chemotherapy and antibiotics** are a major trigger of dysbiosis
- **Damage of the gut ecosystem disrupts** immune homeostasis and barrier integrity
- Vulnerability to inferior clinical outcomes




Malard, F. et al. Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial. eClinicalMedicine 62, 102111 (2023).

Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates



A Premier Portfolio of Full Native and Co-cultured Microbiome Ecosystem Therapies[™] Produced Internally at the Largest European Production Facility Designed for Easy Scalability to Meet Demand

A Strong Pipeline With Multiple Value Inflection Milestones and a Close-to-Market Asset




aGvHD: acute Graft versus Host Disease; IO: Immuno-Oncology; PoC: Proof of Concept; Allo-HSCT: Hematopoietic Stem Cell Transplantation; ALS: Amyotrophic Lateral Sclerosis; IST: Investigator Sponsored Trial; NSCLC: Non-small cell lung cancer


ICI PICASSO: ipilimumab (Yervoy®) and nivolumab (Opdivo®); ICI IMMUNOLIFE: cemiplimab

* R&D partners include AP-HP, Institut Gustave Roussy

** Institut Gustave Roussy, INSERM, Université Paris-Saclay, Bioaster, INRAe, IHU Méditerranée Infection

Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes in Multiple Settings






MaaT013 in aGvHD

Understanding and Addressing Acute Graft-versus-Host Disease (aGvHD)


- → A significant complication following allogeneic hematopoietic stem cell transplantation (Allo-HSCT)
- → May occur in 50% of patients undergoing Allo-HSCT, presence detected typically within the first 100 days post-transplant



 \rightarrow Mortality is primarily linked to the involvement of the gastrointestinal tract

→ Salvage → Ouick action

MaaT013 • aGvHD



 \rightarrow GvHD is characterized by intestinal dysbiosis which is associated with higher mortality in hemato-oncology²


ightarrow In the Early Access Program (EAP), MaaT013 showed efficacy in aGvHD patients who failed 1 to 6 lines of systemic treatment³

ARES: a Pivotal Phase 3 Trial Exploring MaaT013 in Third-Line aGvHD Following Steroid and ruxolitinib Failure

→ Quick action

MaaT013 • aGvHD

Milestones: Topline results announced January 8th 2025 | OS expected by end of 2025 | Regulatory submission expected mid-2025





ARES

13

ARES patients: Baseline Characteristics

Patients characteristics at baseline	All patients receiving MaaT013 (n=66)
Median age, years (range)	55.5 (24; 76)
Gender n (%)	Male: 35 (53%) Female: 31 (47%)
Steroid status n (%)	Steroid-refractory: 57 (86%)
	Steroid-dependent: 9 (14%)
Ruxolitinib status n (%)	ruxolitinib refractory: 66 (100%)
	ruxolitinib intolerant: 0
aGvHD grading (MAGIC*)	Grade I: 0
	Grade II: 6 (9%)
	Grade III: 38 (58%)
	Grade IV: 22 (33%)

🕮 Patients with severe aGvHD

91% are Grade III-IV

*MAGIC : Mount Sinai Acute GVHD International Consortium


100% are ruxolitinib refactory

14

ARES: Strong Response to MaaT013 in aGvHD following Steroid and ruxolitinib Failure

MaaT013 • aGvHD
 ODD EMA/FDA


Quick action



ARES: Unprecedented Probability of Survival Compared to Historical Data with Best Available Therapy (BAT)

MaaT013 • aGvHD

Ouick action




MaaT013 demonstrates response-driven prolonged survival, far exceeding expected outcomes in thirdline aGvHD, with **54% probability of survival at 1 year compared to 15% survival in historical control**

Early Access Program: meeting critical needs in GvHD today and shaping the future

MaaT013 • aGvHD

Quick action



Communicated Phase 3 topline results (62%) in Refractory aGvHD confirm EAP signals (59%)

Clear Regulatory Path for MaaT013 in Third Line Refractory aGvHD

- Eligibility of MaaT013 for the centralized procedure confirmed by EMA (Medicinal product status) and rapporteurs and co-rapporteurs appointed
- Target filing of the EMA Marketing Authorization Application for MaaT013 mid-2025 (6mths in advance vs previous plan)
- Submission based on validated primary endpoint (28 days GI-ORR) complemented with data on 1y-OS
- Target H2 2026 for European marketing authorization, commence commercialization end of 2026

- Open IND: Ongoing dialogue with the FDA to expedite MaaT013 clinical development plan
- Dedicated and optimized study for the US leveraging
 ARES Phase 3 results
- Continue to support the ongoing Expanded Access
 Program to allow US patients early access to MaaT013
- Targeting potential launch of U.S. Phase 3 study in
 2025, subject to appropriate funding








Ouick action

MaaT013 • aGvHD



A Multi-Asset Platform Focused on Oncology

Phoebus: MaaTO33 Phase 2b RCT Potential Adjunctive Treatment for Patients Receiving Allo-HSCT

Design presented at EBMT and ASH



Largest Microbiome RCT trial in oncology

→ Ambulatory

Adjunctive

- → Multicenter Randomized Control Trial
- \rightarrow 56 sites / 6 countries

- → Primary endpoint: **1y-OS**
- \rightarrow Results: Q4-2027
- → **Dec 24: 80 patients** (LPI target date: mid-26)

Ongoing Phase 2b PHOEBUS



Safety Interim analysis on 60 patients in Q1 2025 Based on expected duration
 of recruitment, OS primary
 endpoint expected in 2027

~ 11k patientsper year



Unlocking the Potential of Checkpoint Inhibitors: How Full-Ecosystem Gut Microbiome Overcomes Primary Resistance

Immune Checkpoint Inhibitors (ICI) significantly improve outcomes in solid tumor patients

Primary Resistance Rate to ICIs



Lung Cancer (NSCLC)

35 - 40 %



Skin Cancer (Melanoma) **Up to 65 %**

→ Urgent need for new ICI combination therapies to boost response rates and survival

Leveraging full ecosystem microbiome could be a game-changer in immuno-oncology

2021: FMT from ICI-responders could overcome resistance to ICI in non-responders with metastatic melanoma

⊘ 6/15

Non-responders -> Responders (Davar et al, 2021)

Solution States and the second states of the second states and the second states are second

2023: Microbiotherapy from healthy donors boosts response to aPD1+aCTLA4 in ICI-naive metastatic melanoma patients

✓ 15/20

ICI-naïve → Responders (ORR=75 %, Routy, 2024)

PICASSO studying MaaT013: 1st multicenter RCT **70 pts rand 1:1** 21

MaaT013 Evaluated in Phase 2 Randomized, Multicenter Clinical Trial in Melanoma

Phase 2a PICASSO trial, fully recruited

Investigator Sponsored Trial (Assistance Publique - Hôpitaux de Paris) in collaboration with Institut Gustave Roussy

→ Data expected Q1.25 (positive DSMBs)

Key study endpoints after 23 weeks of treatment:

MaaT013 safety profile and best-overall response rate vs placebo as add-on treatment to Ipilimumab + Nivolumab



MaaT033: Targeting Amyotrophic Lateral Sclerosis Progression



Amyotrophic Lateral Sclerosis (ALS)


- ightarrow Could affect up to 60,000 patients in US & EU by 2040¹
- \rightarrow $\,$ Paralysis and death 3 to 5 years after diagnostic 2
- \rightarrow Currently no curative treatment and few symptomatic treatments

Rationale for Exploratory Utilization of MaaT033 in ALS


- Microbiota-Gut-Brain axis is a multifactorial MoA which has the potential to become the new standard to treat neurodegenerative diseases, including ALS
- → Strong support from medical community & patients
- \rightarrow A capital efficient way of testing neurodegenerative field in the most severe indication with high medical need with potential for expansion

Study

→ Pilot, open-label, Phase 1b study in France, N=15 (NCT05889572)



- → *Key study endpoints*: safety and tolerability of MaaT033 (**Primary**) | gut microbiota composition evolution | marker showing potential impact on disease progression
- Primary endpoint met; full data readout expected in Q1 2025
- MaaT033 found to be safe and well tolerated
- DSMB supports proceeding to Phase 2
- Successful engraftment characterized by the increasing MaaT033 species overtime
 - (Data published in a poster at MNDA, 35th International symposium on ALS/MND)




¹ Arthur, K., Calvo, A., Price, T. et al. Projected increase in amyotrophic lateral sclerosis – from 2015 to 2040. Nat Commun 7, 12408 (2016). <u>https://doi.org/10.1038/ncomms12408</u> I² https://tousensellescontrelasla.fr/la-sla-cest-quoi/

MET-C Product Generation is Driven by MaaT Pharma's Proprietary Predictive AI, Eubiotic Score and *in vitro* and *in vivo* Validation Processes


MET-C • ICI and more





Hematooncology Franchise Driving Value

MaaT013 Addressable Market and Revenues



Potential peak sales of €250m+ worldwide with potential upside from 2L positioning (+1,400 patients)

Realizing value through partnership: Aligning innovation with unmet medical needs in hematology


Unique Franchise Opportunity

- Unique immunosuppressant-sparing, microbiome-based approach
- > Well defined **target population** for both products,
- Prescribers focused on limited number of centers, many of them already using MaaT013
- Proven efficacy and safety with potential to expand to other dysbiosis-linked hematological malignancies (e.g., CAR-T)


Multiple value catalysts over the next few months

Significant potential to leverage partner's expertise in hematology, rare diseases, or hospital commercial operations.

A very meaningful market opportunity








End-to-End In-house cGMP Manufacturing Capabilities

Europe's Largest Specialized cGMP Manufacturing Facility for Microbiome Ecosystem Therapies

O AII MET

A dedicated 1,600m² site (+17,000 sq ft), expandable, to support demands until 2034 for MET-N clinical and future commercial production, R&D, and clinical batches of MET-C products (MaaT034 & MaaT3X family)

~11,000 treatable patients per year





→ cGMP

Leading microbiome therapies fully integrated manufacturing and development platform:

streamlined product development, scaleup and GMP process.



Option to expand manufacturing facilities to double capabilities.



Consistent yield (<10% variation)

Campaign #1 Campaign #2 Campaign #3 Manufacturing yield based on FDA/EMA authorized processes




Currently used at 10% capacity **Scalable up to commercial capacity**




Partnership with





Newsflow & Funding Opportunities



>

Opportunities to fund the Company's development


Cash position of €27m as of September 30,2024

>

Current cash runway into Q2 2025

Exploring several opportunities to fund the Company's developments over the next coming years, **including dilutive and non-dilutive options**





Thank you

